Yu A, et al. Brenner and Rector's The Kidney. 2-Volume Set, 11th edition (Elsevier); 2019.
Sutton RA, Domrongkitchaiporn S. Abnormal renal magnesium handling. Miner Electrolyte Metab 1993; 19:232–240. PMID: 8264509
Elisaf M, et al. Hypomagnesemic hypokalemia and hypocalcemia: Clinical and laboratory characteristics. Miner Electrolyte Metab 1997; 23:105–112. PMID: 9252977
Manohar S, Leung N. Cisplatin nephrotoxicity: A review of the literature. J Nephrol 2018; 31:15–25. doi: 10.1007/s40620-017-0392-z
Pabla N, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296:F505–F511. doi: 10.1152/ajprenal.90545.2008
Houillier P. Mechanisms and regulation of renal magnesium transport. Annu Rev Physiol 2014; 76:411–430. doi: 10.1146/annurev-physiol-021113-170336
Zeidel ML, et al. A new CJASN series: Renal physiology for the clinician. Clin J Am Soc Nephrol 2014; 9:1271. doi: 10.2215/CJN.10191012
de Baaij JHF, et al. Regulation of magnesium balance: Lessons learned from human genetic disease. Clin Kidney J 2012; 5 (Suppl 1):i15-i24. doi: 10.1093/ndtplus/sfr164
Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7:1713–1721. doi: 10.2215/CJN.02780312
Workeneh BT, et al. Hypomagnesemia in the cancer patient. Kidney360 2021; 2:154–166. doi: https://doi.org/10.34067/KID.0005622020
Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25:47–58. doi: 10.1053/ctrv.1999.0097
Huang C, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18:2649–2652. doi: 10.1681/ASN.2007070792
Crona DJ, et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017; 22:609–619. doi: 10.1634/theoncologist.2016-0319